Moxonidine

Drug Profile

Moxonidine

Alternative Names: BDF 5895; BE 5895; Cynt; Moxodin; Normoxin; Physiotens

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Giulini
  • Class Centrally-acting antihypertensives; Heart failure therapies; Imidazoles; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Imidazoline I1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 26 Nov 2003 A study has been added to the adverse events and Heart Failure therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top